Treatment Guideline Chart

Age-related macular degeneration is a common, chronic, progressive, degenerative disease that causes central loss of vision due to abnormalities that occurs in the pigment, neural and vascular layers of the macula.
The macular disorder may have one or more of the following:
- Formation of drusen which are localized deposits of extracellular material usually concentrated in the macula
- Abnormalities in the retinal pigment epithelium (eg hypopigmentation or hyperpigmentation)
- Retinal pigment epithelium and choriocapillaris geographic atrophy                                                                                                                                                                                                            - Neovascular (exudative) maculopathy                                                                                                                                                                                                                                                      - Choroidal neovascularization (CNV), polypoidal choroidal vasculopathy (PCV), reticular pseudodrusen, or retinal angiomatous proliferation

Decreased central vision and distortion of seeing straight lines are the most common symptoms.

Age-related%20macular%20degeneration Diagnosis


Classification of Age-Related Macular Degeneration (AMD) by Age-Related Eye Disease Study (AREDS)1

  • Used in predicting the risk of progression from early to late AMD and visual loss

No AMD (AREDS category 1)

  • No drusen or presence of few small drusen (<63 microns in diameter)

Early AMD (AREDS category 2)

  • Presence of any or all of the following:
    • Multiple small drusen
    • Few intermediate drusen (63-124 microns in diameter) or
    • Mild abnormalities in the RPE
  • Have low risk of progressing to advanced AMD after 5 years

Intermediate AMD (AREDS category 3)

  • Presence of any or all of the following:
    • Extensive intermediate drusen
    • At least one large drusen (≥125 microns in diameter) or
    • Geographic atrophy not involving the center of the fovea

Advanced AMD (AREDS category 4)

  • Geographic atrophy that involves the center of the fovea and/or any of the manifestations of neovascular AMD

Neovascular Age-Related Macular Degeneration (AMD) Classification by Location Seen in Fundus Fluorescein Angiography (FFA)2

  • Helps in identifying specific treatment to give the patient


  • Lesion located ≥200 micrometers from the geometric center of the fovea


  • Lesion located between 1 and 199 micrometers from the geometric center of the fovea


  • Lesion located under the center of the foveal avascular zone

Neovascular Age-Related Macular Degeneration Classification by Angiographic Patterns of Fluorescence1

  • Helps in identifying specific treatment to give the patient

Classic Choroidal Neovascularization (CNV)

  • Bright, well-demarcated, uniform hyperfluorescence in the early phase of FFA and then at the late phase of the angiogram it shows leakage that obscures the boundaries

Occult Choroidal Neovascularization (CNV)

  • Characterized by either:
    • An area of irregular elevation the RPE (fibrovascular pigment epithelial detachment) that appears as stippled hyperfluorescence present in the midphase of the angiogram or
    • Leakage from an undetermined source that appears as speckled hyperfluorescence within dye pooled in the subretinal space

1Modified from: Flaxel CJ, Adelman RA, Bailey ST, et al. Age-related macular degeneration Preferred Practice Pattern®. Ophthalmology. Jan 2020.

2Modified from: The Royal College of Ophthalmologists. Age-related macular degeneration guidelines for management. Feb 2009.


Non-Neovascular/Non-Exudative/Early/Dry Age-Related Macular Degeneration (AMD)

  • Clinical presentation:
    • Soft drusen ≥63 microns in diameter that causes areas of hyperpigmentation in the outer retina or choroid
    • Areas of hypopigmentation of the RPE as a result of gradual breakdown of the RPE
    • Photoreceptors has loss of function
  • Usually of ischemic cause

Neovascular/Exudative/Late/Wet Age-Related Macular Degeneration (AMD)

  • Clinical presentation:
    • Presence of CNV which is the perforation of the choriocapillaris vessels and growth through the Bruch’s membrane and entry to the subretinal pigment epithelial and/or subretinal spaces
    • Serous and/or hemorrhagic detachment of the sensory retina or RPE
    • Presence of hard exudates in the retina
    • Fibrovascular proliferation in the subretina and sub-RPE
    • Presence of disciform scar
  • Usually due to leakage of fluid from blood vessels


  • Ocular history especially presence of precursor lesions
  • Family history especially AMD
  • Medical history including any hypersensitivity reactions
  • Social history especially smoking
  • Medications and nutritional supplements

Physical Examination

Ocular Evaluation

  • Dilated eye exam using binocular slit-lamp biomicroscopy reveals any of the following:
    • Presence of drusens that appears as bright yellow spots or pale yellow spots
    • Presence of geographic atrophy that appears as sharply demarcated or defined and scalloped edges of partial or complete depigmentation as a result of RPE atrophy
    • Lesions indicating risk for progression to advanced AMD (eg large drusen, soft indistinct drusen, extensive drusen area, hyperpigmentation)
    • Signs of exudative AMD like subretinal or sub-RPE neovascularization that appears as gray green lesions, serous detachment of the neurosensory retina, RPE detachment, hemorrhages in the subretinal pigment epithelium, subretina, intraretina or preretina and breakthrough bleeding into the vitreous may occur, hard exudates within the macular area, epiretinal, intraretinal, subretinal or sub-pigment epithelial scar/glial tissue or fibrin like deposits, retinal angiomatous proliferations and retinochoroidal anatomists

Retinal Imaging

Fundus Autofluorescence

  • Helps demonstrate areas of geographic atrophy and monitor their progression
  • May be used to quantify lipofucsin in the RPE

Fundus Fluorescein Angiography (FFA)

  • Gold standard for diagnosing CNV in AMD as it confirms the presence of CNV and its extent, type, size and location
  • Detects persistent or recurrent CNV following treatment
  • Recommended to perform when the patient complains of new metamorphopsia with blurring of vision and/or if physical examination reveals elevation of the RPE, or retina, macular edema, subretinal blood, hard exudates or subretinal fibrosis, or if the optical coherence tomography (OCT) manifests evidence of fluid
  • Helps to determine the cause of visual loss that is not explained by clinical examination
  • Used to guide treatment using Verteporfin photodynamic therapy (PDT) or laser photocoagulation surgery

Fundus Photography

  • Once angiography is done, color fundus photography can be done to:
    • Locate the pathology of the different tissue layers
    • Evaluate sensory retina serous detachments
    • Identify the cause of blocked fluorescence
  • Stereoscopic color photographs records the appearance of the macular retina that can be used as baseline in patients with advanced non-neovascular AMD and in follow-up of patients that has been treated

Indocyanine Green (ICG) Angiography

  • The alternative dye, indocyanine green, is used to delineate choroidal vessel morphology and circulation
    • Penetrates hemorrhage and RPE better than FFA
  • Useful in the assessment of specific forms of AMD such as pigment epithelium detachment (PED), poorly defined CNV, occult CNV, and lesions including retinal angiomatous proliferation or idiopathic PCV

Optical Coherence Tomography (OCT)

  • Provides cross-sectional view of the retina that can identify soft drusen, RPE detachments, subretinal and intraretinal fluid, CNV, cystoid macular edema, as well as the integrity of the photoreceptor and RPE layers
  • Helps to distinguish causes of visual loss that are not directly associated with AMD (eg subtle epiretinal membrane or vitreomacular traction)
  • Allows evaluation of the RPE and photoreceptor layer to identify the anatomic causes of metamorphopsia and visual acuity loss
  • Helps determines the presence of subretinal fluid and degree of retinal thickening which are the earliest manifestations of neovascularization
  • Accurately follows the structural changes that can be used in evaluating the retina and RPE response to therapy

Optical Coherence Tomography Angiography (OCTA)

  • Provides noninvasive assessment of the retinal and choroidal vasculature
  • Useful test to detect new or recurrent neovascular disease activity and helps guide therapy
Editor's Recommendations
Special Reports